Overview

Phase I Study PK Study With OXP005 and Naprosyn

Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The Sponsor is developing a new form of naproxen (the study drug, OXP005), for the potential treatment of rheumatic and painful conditions. The study will compare the study drug to an already marketed formulation of prescription strength naproxen (Naprosyn® the reference product) by looking at how a single dose of the drug is taken up by the body. The safety and tolerability of the drug will also be assessed.
Phase:
Phase 1
Details
Lead Sponsor:
Oxford Pharmascience Ltd
Treatments:
Naproxen